opolimogene capmilisbac (ADU-741) / Novartis - LARVOL DELTA

Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC). (ASCO 2019) - P1; "JNJ-809 has a manageable safety profile consistent with that of other LADD-Lm-based therapies. Observed activation of immune responses with monotherapy did not translate into clinical activity, and further development of JNJ-809 will likely require a combination approach. Clinical trial information: NCT02625857"

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. (PubMed, Prostate Cancer Prostatic Dis) - "JNJ-809 has manageable safety consistent with other LADD Lm-based therapies. Limited antigen-specific immune responses were observed, which did not translate into objective clinical responses."

Clinical • Journal • Fatigue • Gastrointestinal Disorder • Genito-urinary Cancer • Hypertension • Oncology • Prostate Cancer • Solid Tumor • IFNG • IL10 • TNFA